Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3

Biochemical Pharmacology

Volumn 51, Issue 6, 1996, Pages 797-804

  Sahu, Arvind ^a   Pangburn, Michael K ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

autoimmune diseases; complement C3; complement inhibitors; DOPA; immune complex diseases; ischemia; transplantation

Indexed keywords

4 METHOXYPHENYLALANINE; 5 HYDROXYDOPAMINE; ACETOHYDROXAMIC ACID; ADRENALIN; ADRENALIN DERIVATIVE; CARBOHYDRATE; CATECHIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT INHIBITOR; DOPA; DOPA DERIVATIVE; DOPAMINE; GLUCOSE; HYDROXAMIC ACID DERIVATIVE; HYDROXYL GROUP; NORADRENALIN; OXIDOPAMINE; PHENOL; PHENOL DERIVATIVE; PHENYLALANINE; SALICYLHYDROXAMIC ACID; THIOESTER; THREONINE; TYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HEMOLYSIS; HYDROXYLATION; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RABBIT; SHEEP ERYTHROCYTE; STRUCTURE ACTIVITY RELATION;

EID: 0029865548     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02398-4     Document Type: Article

References (46)

1. Holmskov U, Malhotra R, Sim RB and Jensenius JC, Collections: Collagenous C-type lectins of the innate immune defense system. Immunol Today 15: 67-74, 1994.
2. Tack BF, Harrison RA, Janatova J, Thomas ML and Prahl JW, Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77: 5764-5768, 1980.
3. Pangburn MK, Spontaneous reformation of the intramolecular thioester in complement protein C3 and low temperature capture of a conformational intermediate capable of reformation. J Biol Chem 267: 8584-8590, 1992.
4. DeBruijn MHL and Fey GH, Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 82: 708-712, 1985.
5. Pangburn MK and Müller-Eberhard HJ, The alternative pathway of complement. Springer Semin Immunopathol 7: 163-192, 1984.
6. 2-macroglobulin with proteinases. Characteristics and specificity of the reaction and a hypothesis concerning it molecular mechanism. Biochem J 133: 709-724, 1973.
7. Law SKA, Dodds AW and Porter RR, A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 3: 1819-1823, 1984.
8. Dodds AW and Law SKA, Structural basis of the binding specificity of the thioester-containing proteins, C4, C3 and alpha-2-macroglobulin. Complement 5: 89-97, 1988.
9. Isenman DE and Young JR, The molecular basis for the difference in immune hemolysis activity of the Chido and Rogers isotypes of human complement component C4. J Immunol 132: 3019-3027, 1984.
10. Carroll MC, Fathallah DM, Bergamaschini L, Alicot EM and Isenman DE, Substitution of a single amino acid (aspartic acid for histidine) converts the functional activity of human complement C4B to C4A. Proc Natl Acad Sci USA 87: 6868-6872, 1990.
11. Reilly BD, Skanes VM and Levine RP, Evidence showing that the 1105 and 1106 isotypic residues of the fourth component of human complement, C4A, are not involved in amide bond fomation. Mol Immunol 31: 761-769, 1994.
12. Sahu A, Kozel TR and Pangburn MK, Specificity of the thioester-containing site of human C3 and its significance to complement activation. Biochem J 302: 429-436, 1994.
13. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong K and Inoue K, C5 convertase of the alternative complement pathway: Covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 141: 3895-3901, 1988.
14. 1 heavy chain. J Biol Chem 268: 5866-5871, 1993.
15. Sahu A and Pangburn MK, Covalent attachment of human complement C3 to IgG: Identification of the amino acid residue involved in ester linkage formation. J Biol Chem 269: 28997-29002, 1994.
16. Kim YU, Carroll MC, Isenman DE, Nonaka M, Pramoonjago P, Takeda J, Inoue K and Kinoshita T, Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation. J Biol Chem 267: 4171-4176, 1992.
17. Takata Y, Kinoshita T, Kozono H, Takeda J, Tanaka E, Hong K and Inoue K, Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J Exp Med 165: 1494-1507, 1987.
18. Kozono H, Kinoshita T, Kim YU, Takata-Kozono Y, Tsunasawa S, Sakiyama F, Takeda J, Hong K and Inoue K, Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b. J Biol Chem 265: 14444-14449, 1990.
19. Mold C, Nemerow GR, Bradt BM and Cooper NR, CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol 140: 1923-1929, 1988.
20. Marquart HV, Svehag S and Leslie RGO, CR2 is the primary-acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J Immunol 153: 307-315, 1994.
21. Hammer CH, Wirtz GH, Renfer L, Gresham HD and Tack BF, Large scale isolation of functionally active components of the human complement system. J Biol Chem 256: 3995-4006, 1981.
22. Pangbum MK, A fluorometric assay for native C3. The hemolytically active form of the third component of human complement. J Immunol Methods 102: 7-14, 1987.
23. Götze O and Müller-Eberhard HJ, The C3-activator system: An alternative pathway of complement activation. J Exp Med 134: 90s-108s, 1971.
24. Lesavre PH, Hugli Te, Esser AF and Müller-Eberhard HJ, The alternative pathway C3/C5 convertase: Chemical basis of factor B activation. J Immunol 123: 529-534, 1979.
25. Pangburn MK and Müller-Eberhard HJ, The C3 convertase of the alternative pathway of human complement. Enzymatic properties of the biomolecular proteinase. Biochem J 235: 723-730, 1986.
26. Sahu A and Pangburn MK, Tyrosine is a potential site for covalent attachment of activated complement component C3. Mol Immunol 32: 711-716, 1995.
27. Roberts JD and Caserio MC, Basic Principles of Organic Chemistry, pp. 954-962. W. A. Benjamin, New York, 1965.
28. Baba AS and Tamura N, Influence of aromatic compounds on the interaction of activated C4 with EAC1. Immunology 32: 251-256, 1977.
29. Sim RB, Twose TM, Paterson DS and Sim E, The covalent-binding reaction of complement component C3. Biochem J 193: 115-127, 1981.
30. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB and Moore FDJ, Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 149: 1723-1728, 1992.
31. Pemberton M, Anderson G, Vetvicka V, Justus DE and Ross GD, Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol 150: 5104-5113, 1993.
32. Rubin BB, Smith A, Liauw S, Isenman DE, Romaschin AD and Walker PM, Complement activation and white cell sequestration in postischemic skeletal muscle. Am J Physiol 259: H525-H531, 1990.
33. Vasthare US, Rosenwasser RH, Barone FC and Tuma RF, Involvement of the complement system in cerebral ischemic and reperfusion injury. FASEB J 7: A424, 1993.
34. Moore FD Jr, Therapeutic regulation of the complement system in acute injury states. Adv Immunol 56: 267-299, 1994.
35. Kilgore KS, Friedrichs GS, Homeister JW and Lucchesi BR, The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 28: 437-444, 1994.
36. McGeer PL, Rogers J and McGeer EG, Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 8: 149-158, 1994.
37. Jiang H, Burdick D, Glabe CG, Cotman CW and Tenner AJ, β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152: 5050-5059, 1994.
38. Aisen PS and Davis KL, Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 151: 1105-1113, 1994.
39. Walker DG and McGeer PL, Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res 14: 109-116, 1992.
40. Wang MW, Johnson PS, Wright LJ, Lim SM and White DJ, Immunofluorescent localization of pig complement component 3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts. Histochem J 24: 102-109, 1994.
41. Leventhal JR, Matas AJ, Sun LH, Reif S, Bolman RM3, Dalmasso AP and Platt JL, The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 56: 1-8, 1993.
42. Bach FH, Turman MA, Vercellotti GM, Platt JL and Dalmasso AP, Accommodation: A working paradigm for progressing toward clinical discordant xenografting. Transplant Proc 23: 205-207, 1991.
43. Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J and Nilsson U, Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 14: 46-53, 1990.
44. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A and Mollnes TE, Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 103: 806-813, 1992.
45. Cheung AK, Complement activation as index of haemodialysis membrane biocompatibility: The choice of methods and assays. Nephrol Dial Transplant 9: 96-103, 1994.
46. Johnson RJ, Complement activation during extracorporeal therapy: Biochemistry, cell biology and clinical relevance. Nephrol Dial Transplant 9: 36-45, 1994.